Literature DB >> 18541783

Failure of Japanese encephalitis vaccine and infection in inducing neutralizing antibodies against West Nile virus, People's Republic of China.

Fang Tang1, Jiu-Song Zhang, Wei Liu, Qui-Min Zhao, Fang Zhang, Xiao-Ming Wu, Hong Yang, Hinh Ly, Wu-Chun Cao.   

Abstract

We examined whether live attenuated Japanese encephalitis (JE) vaccine is effective in preventing West Nile virus (WNV) infection in the People's Republic of China. Three groups were recruited into the study: patients with Japanese encephalitis (JE), healthy controls vaccinated with live attenuated 2 SA14-14-vaccine against JE virus (JEV), and unvaccinated healthy controls. Serum samples were collected and screened for IgG antibodies against JEV by an indirect immunofluorescence assay. Positive samples were then analyzed for levels of antibodies against JEV and neutralizing antibodies against West Nile virus (WNV) by a plaque-reduction neutralization test (PRNT). Although most persons had medium to high levels of JEV-reactive IgG and neutralizing antibodies, only 2 of the 82 unvaccinated control samples were positive for the WNV-reactive antibodies. These findings suggest that previous JEV infection or vaccination did not induce adequate levels of WNV-reactive antibodies in the population studied. However, how these persons would respond to a secondary flavivirus infection and whether their prior experience with wild-type or attenuated JE vaccine will provide some cross-protection against WNV disease still warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541783

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  9 in total

Review 1.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice.

Authors:  Na Li; Zhe-Rui Zhang; Ya-Nan Zhang; Jing Liu; Cheng-Lin Deng; Pei-Yong Shi; Zhi-Ming Yuan; Han-Qing Ye; Bo Zhang
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

3.  High throughput quantitative colorimetric microneutralization assay for the confirmation and differentiation of West Nile Virus and St. Louis encephalitis virus.

Authors:  Michael Taketa-Graham; Jaime L Powell Pereira; Elizabeth Baylis; Cynthia Cossen; Leopoldo Oceguera; Peter Patiris; Robert Chiles; Carl V Hanson; Bagher Forghani; BagHer Forghani
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

4.  PCP consensus sequences of flaviviruses: correlating variance with vector competence and disease phenotype.

Authors:  Petr Danecek; Wenzhe Lu; Catherine H Schein
Journal:  J Mol Biol       Date:  2009-12-04       Impact factor: 5.469

5.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Authors:  Mario Lobigs; Megan Pavy; Roy A Hall; Päivi Lobigs; Peter Cooper; Tomoyoshi Komiya; Hiroko Toriniwa; Nikolai Petrovsky
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

Review 6.  Global emergence of West Nile virus: Threat & preparedness in special perspective to India.

Authors:  Pritom Chowdhury; Siraj Ahmed Khan
Journal:  Indian J Med Res       Date:  2021-07       Impact factor: 2.375

Review 7.  Cross-Reactive Immunity among Five Medically Important Mosquito-Borne Flaviviruses Related to Human Diseases.

Authors:  Baohua Hou; Hui Chen; Na Gao; Jing An
Journal:  Viruses       Date:  2022-06-02       Impact factor: 5.818

8.  Protection of a single dose west nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus.

Authors:  Teresa Merino-Ramos; Ana-Belén Blázquez; Estela Escribano-Romero; Rodrigo Cañas-Arranz; Francisco Sobrino; Juan-Carlos Saiz; Miguel A Martín-Acebes
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

9.  A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice.

Authors:  Na Li; Zhe-Rui Zhang; Ya-Nan Zhang; Jing Liu; Cheng-Lin Deng; Pei-Yong Shi; Zhi-Ming Yuan; Han-Qing Ye; Bo Zhang
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.